Eris Lifesciences to fully own Swiss Parenterals

is set to acquire the remaining 30% stake in its injectables subsidiary Swiss Parenterals for Rs 423 crore, moving from 70% to 100% ownership to consolidate control, simplify decision-making, and integrate export-led sterile capabilities with its branded formulations strategy in India and emerging markets. The board scheduled a meeting on November 24, 2025 to consider issuing equity shares via a preferential allotment potentially for consideration other than cash and to seek shareholder approval through an EGM or postal ballot, indicating a capital efficient structure to fund the buyout while preserving liquidity. This step follows Eris’s February 2024 move to enter sterile injectables by acquiring 51% of Swiss Parenterals (and the promoter group simultaneously taking 19%), a deal designed to add EU/TGA/Anvisa-accredited capacity, open RoW export channels, and complement Eris’s domestic brands portfolio, thereby enhancing growth visibility and operating leverage post full consolidation. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.